GIST originates in stromal tissue, differentiating it from epithelial-based GI cancers, and is classified as a sarcoma. Symptoms include fullness, fatigue, and GI bleeding, necessitating awareness and ...

A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...

Mutational profiling is crucial for selecting effective targeted therapies for GIST, replacing broad-spectrum treatments. Localized treatment options, including surgery and ablation, help manage side ...

About 1,200 Germans are diagnosed with gastrointestinal stromal tumors every year—a rare type of cancer in which the tumors develop in the walls of the digestive organs and quickly develop resistance ...

Gastrointestinal stromal tumors (GISTs) are common tumors of the gastrointestinal tract. Endoscopic resection offers minimally invasive advantages, but its long-term outcomes versus surgery remain ...

Ripretinib as preoperative therapy in patients with potentially resectable advanced gastrointestinal stromal tumors after imatinib failure: Final analysis of a prospective, multicenter study. This is ...